Pharmaceuticals ETF (IHE) Hits a New 52-Week High

Impact · against what's priced in

The Jefferies price target increase for Eli Lilly is not a catalyst because the market already excludes the bull case for sustained GLP-1 growth. The news simply reinforces the existing divide between current pricing and the most optimistic analyst projections.

LLY+0.10

Challenges what's priced in

The price assumes

Sustaining growth above 30% beyond 2026

Jefferies' $1,700 target is based on underappreciated international GLP-1 growth; however, the current price explicitly rejects the bull case for sustained dominance required to grow above 30%.

What LLY's price assumes · Sep 10

• healthcare
• m and a
• pharmaceuticals
• LLY
• etf
• glp 1
• momentum
• price target

Search tags